Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.

David G CoffeyKeren OsmanAdolfo AlemanSelma BekriSimone KatsAmishi DhadwalDonna CatameroSeunghee Kim-SchulzeSacha GnjaticAjai ChariSamir ParekhSundar JagannathHearn Jay Cho

Published in: Journal for immunotherapy of cancer (2024)

NCT02655458.

Keyphrases

multiple myeloma
stem cells
cell therapy
open label
bone marrow
platelet rich plasma
placebo controlled
double blind
clinical trial
randomized controlled trial
mesenchymal stem cells
high dose